T A B L E O F C O N T E N

Main results
Seven trials with a total of 4895 patients were included in the review. The quality of the evidence was high for most outcomes but was downgraded to moderate for the outcome catheter-related bloodstream infection (CRBSI). The downgrade was due to wide confidence intervals, which created a high level of uncertainty around the effect estimate. CRBSI was assessed in five trials (4806 patients). There was no significant between group difference in the CRBSI rate (clinically-indicated 1/2365; routine change 2/2441). The risk ratio (RR) was 0.61 (95% CI 0.08 to 4.68; P = 0.64). No difference in phlebitis rates was found whether catheters were changed according to clinical indications or routinely (clinically-indicated 186/2365; 3-day change 166/2441; RR 1.14, 95% CI 0.93 to 1.39). This result was unaffected by whether infusion through the catheter was continuous or intermittent. We also analysed the data by number of device days and again no differences between groups were observed (RR 1.03, 95% CI 0.84 to 1.27; P = 0.75). One trial assessed allcause bloodstream infection. There was no difference in this outcome between the two groups (clinically-indicated 4/1593 (0.02%); routine change 9/1690 (0.05%); P = 0.21). Cannulation costs were lower by approximately AUD 7.00 in the clinically-indicated group (mean difference (MD) -6.96, 95% CI -9.05 to -4.86; P ≤ 0.00001).
Authors' conclusions
The review found no evidence to support changing catheters every 72 to 96 hours. Consequently, healthcare organisations may consider changing to a policy whereby catheters are changed only if clinically indicated. This would provide significant cost savings and would spare patients the unnecessary pain of routine re-sites in the absence of clinical indications. To minimise peripheral catheter-related complications, the insertion site should be inspected at each shift change and the catheter removed if signs of inflammation, infiltration, or blockage are present.
P L A I N L A N G U A G E S U M M A R Y
Replacing a peripheral venous catheter when clinically indicated versus routine replacement
Background
Most hospital patients receive fluids or medications via an intravenous catheter at some time during their hospital stay. An intravenous catheter (also called an IV drip or intravenous cannula) is a short, hollow tube placed in the vein to allow administration of medications, fluids or nutrients directly into the bloodstream. These catheters are often replaced every three to four days to try to prevent irritation of the vein or infection of the blood. However, the procedure may cause discomfort to patients and is quite costly.
Study characteristics and key results
This review included all of the randomised controlled trials (current up to March 2015), which have compared routine catheter changes with changing the catheter only if there were signs of inflammation or infection. We measured catheter-related blood stream infection, phlebitis and other problems associated with peripheral catheters, such as local infection and catheter blockage. There was no difference between the groups on any of these measures. However, we did find that it costs less, on average, when catheters were replaced when there was a clinical indication to do so, compared with routine changes.
Quality of the evidence
The overall quality of the evidence was rated as being high for most of the outcomes. There was some uncertainty for the outcome 'catheter related blood stream infection', so the evidence for that outcome was downgraded to moderate. We found no evidence of benefit to support current practice of changing catheters routinely every three to four days.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Clinically-indicated versus routine changes for peripheral venous catheter-related complications In support of the rating, the guideline cites two observational studies (Lai 1998; Tager 1983 ) and one RCT. The first observational study followed 3094 patients through their period of IV peripheral catheterisation and found that the phlebitis rate was 3.2% among those whose catheters remaining in situ for > seven days, compared with a rate of 4.1% and 3.9% for those whose dwell times were three and four days respectively (Tager 1983) . The second observational study compared intravenous catheters left in place for 72 hours or 96 hours and found equivalent phlebitis rates (Lai 1998). The one RCT that was cited was designed to compare two types of catheter material, not dwell times (Maki 1991) . The guideline also exempts children or patients with poor veins from the recommendation. In recent years, there have been improvements in catheter design and composition and more recent studies, including an earlier version of this review (Webster 2010) , indicate that the recommendation may need to be revised. On the other hand, based on level 1 evidence, the most recent Infusion Nursing Standards of Practice and the epic3 National Evidence Based Guidelines recommend that short peripheral catheters should be replaced when clinically indicated, unless the patient is receiving parenteral nutrition peripherally (Infusion Nurses Society 2011; Loveday 2014). The projected 5-year savings from implementing clinically indicated peripheral intravenous catheter removal policies is US$300 million and 1 million health-worker hours in the United States alone (Tuffaha 2014; Tuffaha 2014a). 
Description of the condition
Description of the intervention
The intervention under consideration is replacing an intravenous peripheral catheter only if there are clinical indications to do so. Clinical indications include blockage, pain, redness, infiltration, swelling, leakage, and phlebitis.
How the intervention might work
Each time a catheter is inserted, the patient's skin integrity is breached and a potential portal for pathogens is provided. For example, Uslusoy found a significant relationship between the number of times infusions were inserted and phlebitis (Uslusoy 2008) . Consequently, it may be prudent to limit the frequency of peripheral catheter changes as long as there is no clinical reason to do so. There is some support for this approach from observational studies that have compared outcomes between catheters remaining in situ for varying periods. In an adequately powered observational study, which included patients from medical wards and intensive care units, the investigators were unable to demonstrate any increased risk of phlebitis beyond the second day (Bregenzer 1998). Similarly, in a retrospective study of 784 intravenous catheter starts the rate of phlebitis on days one and two was 11.5%, dropping to 3.9% by day four (Homer 1998). The authors concluded that "there appeared to be less risk in continuing therapy beyond the third day than re-starting the therapy" (pp 304). Catney 2001 also failed to demonstrate any increase in phlebitis rates with the passage of time, with failure rates being less at 144 hours (1.9%) than at 72 hours (2.5%) (Catney 2001) . Similarly, in a prospective investigation of 305 peripheral catheters there were 10 cases of infusion phlebitis amongst patients who had their catheter in situ for less than 72 hours whereas none were reported in patients where the dwell time was longer (White 2001). In the same study, there were three cases of post-infusion phlebitis; these all occurred amongst patients whose peripheral vein infusion catheter had been in place for less than 72 hours. Even among a high risk population of oncology and infectious diseases patients, phlebitis rates were no different when length of cannulation was dichotomised to three days or less and more than three days (Cornely 2002).
Why it is important to do this review
These observational studies create uncertainty around the US Centers for Disease Control (CDC) guidelines relating to peripheral intravenous catheter management. This uncertainty has led some hospitals to adopt the practice of re-siting only where there is evidence of inflammation or infiltration (personal communication). Included in the new CDC recommendations is a statement related to clinically-indicated (Cl I) replacement in adults, advising that this was an "unresolved issue" and referencing the previous version of this review (Webster 2010), which showed 'no difference' between the two approaches to re-siting. Making the guidelines even more difficult to rationalise is the recommendation for peripheral catheter replacement in children, which states "replace peripheral catheters in children only when clinically indicated" (O'Grady 2011). References supporting the 2011 recommendation were unrelated to dwell times (Band 1980; Maki 1973) and may indicate a mistake in the CDC's reference list (p61) (O'Grady 2011). Insertion of a peripheral intravenous catheter can be a painful and traumatic process and, if unnecessary, adds not only to a patient's discomfort but also has significant cost implications for the institution. There is a clear need to provide direction for clinicians through systematically reviewing existing studies.
O B J E C T I V E S
To assess the effects of removing peripheral intravenous (IV) catheters when clinically indicated compared with removing and re-siting the catheters routinely.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) comparing routine removal of peripheral IV catheters with removal only when clinically indicated were considered. Cross-over trials were not eligible for inclusion.
Types of participants
Any patient requiring a peripheral IV catheter to be in situ for at least three days for the administration of intermittent or continuous therapy (this may include patients in hospitals, nursing homes, or in community settings). Participants receiving parenteral fluids were excluded.
Types of interventions
Any duration of time before routine replacement versus clinicallyindicated replacement will be included. Catheters made from any type of material (for example metal, plastic); non-coated or coated with any type of product (for example antibiotic, anticoagulant); or covered by any type of dressing (for example gauze, clear occlusive) were eligible.
Types of outcome measures
Primary outcomes
• Catheter-related blood stream infection (CRBSI) (defined as a positive blood culture from a peripheral vein; clinical signs of infection; no other apparent source for the bloodstream infection except the intravenous catheter; and colonised intravenous catheter tip culture with the same organism as identified in the blood)
• Thrombophlebitis (using any definition identified by the trial author)
• All-cause bloodstream infection (defined as a any positive blood culture drawn from a peripheral vein while an intravenous catheter is in situ or for 48 hours after removal)
• Cost (in terms of materials and labour associated with IV catheter-related insertion)
Secondary outcomes
• Infiltration (defined as permeation of IV fluid into the interstitial compartment, causing swelling of the tissue around the site of the catheter)
• Catheter occlusion or blockage (identified by the inability to infuse fluids)
• Number of catheter re-sites per patient
Search methods for identification of studies
There was no restriction on language. If foreign language studies had been found, we intended to seek initial translation of abstracts for the application of the inclusion and exclusion criteria. Where necessary, the methods, results, and discussion sections would have been translated for inclusion in the review. 
Electronic searches
Searching other resources
We contacted researchers and manufacturers in order to obtain any unpublished data. Reference lists of potentially useful articles were also searched. We also searched the following clinical trials registries;.
• ClinicalTrials.gov (http://clinicaltrials.gov/) (10 April 2015) using the terms peripheral and catheter and routine
• World Health Organization International Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/) (10 April 2015) using the terms peripheral and catheter
Data collection and analysis
Selection of studies
Titles and abstracts identified through the search process were independently reviewed by JW, SO, and CR. Full reports of all potentially relevant trials were retrieved for further assessment of eligibility based on the inclusion criteria. As the review authors were also the investigators on some of the included trials, assessment was allocated to a review author who was not an investigator. Differences of opinion were settled by consensus or referral to a third review author. There was no blinding of authorship.
Data extraction and management
Following Cochrane Vascular recommendations, two review authors independently extracted data to a pre-tested data extraction form. Disagreements were resolved by discussion and, where necessary, by a third review author. We contacted authors of published and unpublished trials for additional information. We extracted the following main sets of data from each included study:
• lead author, date;
• study participant inclusion criteria;
• country where the research was conducted;
• participants' gender and age;
• study design, randomisation processes, allocation concealment;
• intervention descriptions;
• intervention setting (hospital, home, residential aged care facilities);
• numbers of participants in each trial arm, withdrawals and dropouts;
• outcome measures, time(s) at which outcomes were assessed.
The first review author entered the data into RevMan, with another review author checking the data entry accuracy.
Assessment of risk of bias in included studies
Two review authors independently assessed the included studies using the Cochrane Collaboration tool for assessing risk of bias (Higgins 2011a). This tool addresses six specific domains, namely sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other issues (for example extreme baseline imbalance). Disagreements between review authors were resolved by consensus or referral to a third review author. We contacted the investigators of included trials to resolve any ambiguities.
Measures of treatment effect
For individual trials, effect measures for categorical outcomes included risk ratio (RR) with its 95% confidence interval (CI). For statistically significant effects, the number needed to treat (NNT) or number needed to harm (NNH) was calculated. For continuous outcomes the effect measure we used was mean difference (MD) or, if the scale of measurement differed across trials, standardised mean difference (SMD), each with its 95% CI. For any metaanalyses (see below), for categorical outcomes the typical estimates of RR with their 95% CI were calculated; and for continuous outcomes the mean difference (MD) or a summary estimate for SMD, each with its 95% CI, were calculated. Data were analysed using the Cochrane Collaboration's Review Manager (RevMan) 5 software.
Summary of findings tables
To assess the overall body of evidence, we developed a 'Summary of findings' table for the four primary outcomes (catheter-related bloodstream infection; phlebitis; all-cause bloodstream infection; and cost) using GRADEprofiler. The quality of the body of evidence was assessed against five principle domains: 1) limitations in design and implementation; 2) indirectness of evidence or generalisability of findings; 3) inconsistency of results, for example unexplained heterogeneity and inconsistent findings; 4) imprecision of results where confidence intervals were wide; and 5) other potential biases, for example publication bias or high manufacturer involvement (Schnemann 2011).
Unit of analysis issues
It is inadequate merely to compare longer and shorter dwell time intravenous devices (IVDs) on crude incidence of complications; this does not take into account the cumulative daily risk inherent with IVD use. There is clearly a 'per day risk' that is present, and grows with each day of IVD treatment, regardless of how many IVDs are used over the period of therapy. This cannot be extrapolated to mean that restricting (removing) individual IVDs will reduce overall risk. That is, an IVD in situ for seven days has seven days of exposure to risk compared with an IVD in use for only three days, but if the patient requires therapy for seven days in total then using multiple catheters over the period may not reduce risk but merely divide the same risk between multiple catheters. Appropriate time comparisons need to be made using statistics such as Kaplan-Meier analysis, logistic regression, or Cox proportional models. It is vital that the patient is used as the unit of measurement (denominator for comparison), not the IVD. If a patient requires therapy for example for five days, the patient may have one catheter used for the entire time or alternately multiple IVDs used over the five days. If the multiple catheters are viewed independently they may appear to have lower risk per catheter but the total risk for the patient over the five days may be the same. We dealt with this by only including studies where data were available per patient rather than per catheter. Where data were not originally analysed in this format we contacted the investigators (for example Van Donk 2009) to get these data. For comparison, we have also included an analysis of phlebitis per catheter days where this information was available. Cross-over trials were not eligible. There were no cluster randomised trials.
Dealing with missing data
If any outcome data remained missing despite our attempts to obtain complete outcome data from authors, we assessed the risk of bias of the missing data and decided if the missing data were at 'low' or 'high' risk of bias according to our risk of bias criteria (Higgins 2011a). if data were considered to be missing at random, we analysed the available information. If standard deviations were missing, we planned to impute them from other studies or, where possible, compute them from standard errors using the formula SD = SE X √ N where these were available (Higgins 2008).
Assessment of heterogeneity
We explored clinical heterogeneity by examining potentially influential factors, for example intervention dwell time, care setting, or patient characteristics. We assessed statistical heterogeneity using the I 2 statistic (Higgins 2008) . This examines the percentage of total variation across studies due to heterogeneity rather than to chance. Values of I 2 between 50% and 90% may represent substantial heterogeneity and values over 75% indicate a high level of heterogeneity. We carried out statistical pooling on groups of studies which were considered to be sufficiently similar. Where heterogeneity was absent or low (I 2 = 0% to 25%) we used a fixedeffect model; if there was evidence of heterogeneity (I 2 > 25%) we used a random-effects model. If heterogeneity was high (I 2 > 65%) we did not pool the data (Higgins 2003).
Assessment of reporting biases
Reporting bias was assessed using guidelines in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a). Where sufficient study data were available for individual outcomes, funnel plots were developed and inspected for evidence of publication bias.
Data synthesis
Where appropriate, results of comparable trials were pooled using a fixed-effect model and the pooled estimate together with its 95% CI were reported. We conducted a narrative review of eligible studies where statistical synthesis of data from more than one study was not possible or considered not appropriate.
Subgroup analysis and investigation of heterogeneity
We planned to analyse potential sources of heterogeneity using the following subgroup analyses. 1. Type of randomisation (truly randomised versus not reported).
2. Concealment of allocation (adequate versus not reported).
Blinding (patients and clinicians blinded versus open-label).
4. Statement of withdrawals and losses to follow up in each group (stated versus not stated).
5. Intermittent versus continuous infusion.
Sensitivity analysis
We planned to perform sensitivity analyses to explore the effect of the following criteria. 1. Concealment of allocation. 2. Size of studies (< 100 patients versus at least 100 patients). For this update, there were three additional citations which were considered potentially relevant following screening of the search results. Two of these were publications related to an already included study (Rickard 2012) and have been added as supplementary papers. The third was not relevant to this review. No additional trials were found in our search of trials registries.
Included studies
Because three of the authors of this review were also investigators in trials under consideration, we allocated the assessment of those trials to review authors who were not investigators for those particular studies. 
Excluded studies
The 
Risk of bias in included studies
See 
Blinding
It was not possible to blind either the participants or the healthcare providers in any of the trials.
Outcome assessment
Other potential sources of bias
In the Barker 2004 trial there were two definitions of phlebitis, one of which stated that two symptoms were necessary; yet it appears that erythema alone was diagnosed as phlebitis, with severity based on the area of inflammation. The extreme results in the Nishanth 2009 trial, where 100% of participants in the clinicallyindicated group developed phlebitis compared with 9% in the two-day change group, suggests that chance or other unknown bias affected results in this small trial. All of the included studies reported incidence of phlebitis (4895 patients). When results of all trials were combined, heterogeneity was 65%. Consequently, we conducted a sensitivity analysis and removed the two trials with less than 100 participants, both of which used a two-day We also analysed the data by number of device days and, again, no differences between groups were observed (RR 1.03, 95% CI 0.84 to 1.27; P = 0.75) (Analysis 1.3; Figure 6 ). In the two trials using a two-day replacement schedule compared with clinicallyindicated changes (Barker 2004; Nishanth 2009), heterogeneity was over 60% so results were not combined. In the first of these two trials Barker 2004 reported that 11/26 (42.3%) participants in the clinically-indicated group developed phlebitis compared with 1/21 (4.8%) in the two-day change group. Nishanth 2009 diagnosed all of the participants in the clinically-indicated group (21/21; 100.0%) with phlebitis and 2/21 (9.5%) in the two-day group. The pre-planned outcomes 'number of catheter re-sites per patient', 'pain' and 'satisfaction' were not reported by the studies included in the review.
Effects of interventions
Subgroup and sensitivity analysis
We planned to conduct subgroup analyses on 1) Type of randomisation (truly randomised versus not reported); 2) Concealment of allocation (adequate versus not reported) and; 3) Statement of withdrawals and losses to follow up in each group (stated versus not stated). However, there were too few studies in these subgroups to make any meaningful comparisons. Similarly, blinding was not possible in any of the studies. Nor did we conduct any of our preplanned sensitivity analysis (except size of studies for the outcome 'phlebitis') for similar reasons.
D I S C U S S I O N
Summary of main results
This systematic review analysed catheter-related bloodstream infection, phlebitis, other reasons for catheter failure, and cost with the intention of comparing routine catheter changes (at between two and four days) with replacing the catheter only if clinical signs were apparent. The primary outcomes of this review suggest that patients are not adversely affected if the catheter is changed based on clinical indications rather than routinely, as recommended by the US Centers of Disease Control (O'Grady 2011). The rate of catheter-related bloodstream infection was similar in both groups, between 0.0% and 0.3%, and comparable to that previously reported in prospective studies (Maki 2006) . A marginal but non-significant increase in the phlebitis rate in the clinically-indicated group was apparent when data were analysed by patient but became less perceptible when data were analysed per 1000 device days, which is a more clinically useful measure. In addition, most cases of phlebitis are mild in nature, requiring no treatment or removal of the catheter. There was no indication in our review that phlebitis was a precursor to bloodstream infection. Catheter failure due to blockage was more frequent in the clinically-indicated group. This could be expected; all catheters will fail eventually and will need to be replaced if treatment is ongoing. The outcome is not clinically meaningful, it is simply an indicator of the longer dwell times in the clinically-indicated group. Since the 'treatment' for a blocked catheter is replacement of the catheter, it would not be of any benefit to the patient to replace the catheter earlier since it would not reduce the need for replacement, and would instead increase the chance of re-cannulation. Many catheters do not fail over the course of IV treatment, even with extended dwell times.
Cost was significantly less, around AUD 7, in the clinically-indicated group. This result was based on three studies and results were consistent and intuitively logical (fewer catheters, less clinician time and equipment). Although, this is a seemingly small amount, it corresponds to approximately 11% of catheter-related expenditure, which may represent a considerable saving to organisations with high use (Figure 8 ).
Overall completeness and applicability of evidence
Trials included in this systematic review directly addressed the review question and we were able to conduct a number of metaanalyses. Neither pain nor satisfaction were measured in any of the reviewed studies and would be a useful addition to any future trial.
Quality of the evidence
See Summary of findings for the main comparison
Limitations in study design and implementation
Risk of bias was assessed according to six components: sequence generation, allocation concealment, blinding, selective outcome reporting, incomplete follow up, and other potential biases. All of the studies avoided selection bias and ensured allocation concealment. The methodological quality of most of the RCTs was high with one exception. It was not possible to blind the primary outcome in any of the trials. Blinding was not possible because it was necessary to identify the catheter as either 'routine change' or 'clinically indicated', to prevent inadvertent routine replacement of catheters in the intervention group. It is unclear if this had any bearing on outcomes but the review authors argue that it is unlikely (Figure 2; Figure 3 ). In the Barker 2004 and Nishanth 2009 trials, the investigator was directly involved in diagnosing phlebitis; in all of the other studies either medical staff, ward nurses, IV therapy staff, or research nurses evaluated the outcomes. As one author noted, it is routine practice to record reasons for removal of an intravenous catheter in the medical record, and it is unlikely that such entries would be falsified based on group allocation (Webster 2008).
Indirectness of evidence
All of the trials compared routine changes with clinically-indicated changes. However, five trials used a three to four-day change schedule and two trials changed catheters every two days. Consequently, three to four-day results may provide indirect evidence for two-day changes, conversely two-day changes provide indirect evidence for a three to four-day change schedule. Additionally, only one study (Nishanth 2009) included patients who were from a developing country and who were "usually asthenic, many underhydrated/ dehydrated on admission" (personal correspondence), so the evidence may be regarded as indirect for these types of patients.
Unexplained heterogeneity or inconsistency of results
When we combined results of studies that investigated the effect of different catheter replacement schedules on phlebitis, the heterogeneity was high. This was probably due to the different schedules for the routine catheter changes or population differences, or both. Small sample sizes may also have contributed to the extreme results, which caused the heterogeneity. We tested these assumptions by performing a sensitivity analysis, removing two of the seven studies. Results of the five trials are presented in the review text and the Summary of findings table (Summary of findings for the main comparison).
Imprecision of results
Confidence intervals were wide in the pooled outcomes of catheter-related bloodstream infection, local infection, and mortality ( Figure 4 ; Figure 11 ; Figure 12 ) indicating a high level of uncertainty around the effect size. Further research is therefore very likely to have an important impact on the confidence in the estimate of effect for these outcomes.
Publication bias
We feel confident that our comprehensive electronic searches identified all existing, published, randomised controlled trials addressing the review question.
Potential biases in the review process
Although the authors were investigators in one or more of the included trials, clearly described procedures were followed to prevent potential biases in the review process. A careful literature search was conducted and the methods we used are transparent and reproducible. None of the authors has any conflict of interests.
Agreements and disagreements with other studies or reviews
Our results concur with several prospective observational studies, which found no additional risk in extending IVD dwell times (Bregenzer 1998; Catney 2001; Homer 1998; White 2001) . We believe the reason for this is the similarity in the mean dwell times between the intervention and control arms. Each of the included studies were pragmatic trials and, in real life, many catheters are not changed within the prescribed time frames. For example, in three-day protocols the 72-hour period may occur in the middle of the night; or a decision may be made to leave an existing catheter in place if the patient is due for discharge the following day or if they are thought to have poor veins. Conversely, the catheter may need to be removed early in any clinically-indicated group if the patient's catheter becomes blocked or infiltration or phlebitis occurs, or the patient is discharged within a couple of days of catheter insertion. Our results also support the CDC guidelines for peripheral catheter replacement in children, which state "replace peripheral catheters in children only when clinically indicated" (O'Grady 2011). Similarly, in a guideline for timing peripheral intravenous replacement (Ho 2011) findings from the original version of this review were replicated (Webster 2010).
A U T H O R S ' C O N C L U S I O N S Implications for practice
The review found no difference in catheter-related bloodstream infection or phlebitis rates whether peripheral intravenous catheters are changed routinely every 72 to 96 hours or when clinically indicated. The consistency in these results, which include a very large multi-site study, indicate that healthcare organisations should adopt a clinically-indicated replacement policy. This would provide significant cost savings and would also be welcomed by patients, who would be spared the unnecessary pain of routine resites in the absence of clinical indications. Busy clinical staff would also reduce time spent on this intervention. To minimise peripheral catheter-related complications, the insertion site should be inspected at each shift change and the catheter removed if signs of inflammation, infiltration, or blockage are present.
Implications for research
Any future trial should use standard definitions for phlebitis and be sufficiently large to show true differences. Based on results from the meta-analysis in this review, at least 2500 participants would be required in each arm of any future trial to show a lowering of phlebitis rates from 8% to 6% (α = 0.05 and 80% power). Neither pain nor satisfaction were measured in any of the reviewed studies and would be a useful addition to any future trial. Although costs were estimated in some of the included trials, a careful economic analysis of routine versus clinically-indicated replacement would be helpful for healthcare administrators. There was also some evidence from this review that different results may occur when the population is drawn from a developing country. Consequently, trials conducted in a wider variety of healthcare systems would add to the external validity of the review's results.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies
Interventions
Clinically indicated: Catheters were removed if the site became painful, the catheter dislodged or there were signs of PVT Routine replacement: Catheters were replaced every 48 hours.
Outcomes Primary: Incidence of PVT defined as "the development of two or more of the following: pain, erythema, swelling, excessive warmth or a palpable venous cord" Notes PVT was defined as "the development of two or more of the following: pain, erythema, swelling, excessive warmth or a palpable venous cord". However, in the discussion, the author stated that "even a small area of erythema was recorded as phlebitis" (i.e., only one sign)
It is unclear what proportion of patients were on continuous infusion Catheters were inserted "at the instruction of the principal investigator" "All patients were reviewed daily by the principal investigator, and examined for signs of PVT at the current and all previous infusion sites" High risk Evidence for participants: Quote "unblinded study".
Evidence for personnel: As above.
Evidence for outcomes: As above.
Incomplete outcome data (attrition bias) All outcomes Low risk Comment: Data for all patients were available.
Selective reporting (reporting bias) Low risk Comment: Stated outcomes were reported but original protocol not sighted
Other bias Unclear risk Extreme results: In this small trial, 100% of participants in the clinically indicated group developed phlebitis compared with 9% in the 2-day change group, which suggests that chance or other unknown bias affected results Outcomes Primary: Phlebitis per patient and per 1000 device days (phlebitis was defined as a total score of 2 or more points from the following factors: pain (on a 10-point scale, 1 = 1 point, and 2 or more = 2 points; redness (less than 1cm = 1 point, and 1 or more cm = 2 points); swelling (as for redness); and discharge (haemoserous ooze under dressing = 1 point, and haemoserous ooze requiring dressing change or purulence = 2 points) Also reported on: Suspected IVD-related bacteraemia and occlusion/blockage. Heterogeneity: Chi 2 = 1.11, df = 2 (P = 0.57); I 2 =0.0%
Rickard 2010
Methods
Notes
Risk of bias
Test for overall effect: Z = 6.51 (P < 0.00001) 
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
The primary outcome was changed to catheter-related bloodstream infection; all-cause bloodstream infection was added as a separate primary outcome. This was done to more closely differentiate between the two outcomes.
The methodological quality assessment of the included studies has been updated to the Cochrane Collaboration tool for assessing risk of bias (Higgins 2011a). 
I N D E X T E R M S Medical Subject Headings (MeSH)
MeSH check words
Humans
